# Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine

> **NCT05192265** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Ibadan** · enrollment: 172 (actual)

## Conditions studied

- Malaria Fever
- Plasmodium Falciparum Malaria
- Uncomplicated Malaria

## Interventions

- **DRUG:** Antimalarials, pyronaridine-artesunate
- **DRUG:** Antimalarials, Artemether + Lumefantrine

## Key facts

- **NCT ID:** NCT05192265
- **Lead sponsor:** University of Ibadan
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-20
- **Primary completion:** 2020-12-23
- **Final completion:** 2020-12-23
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05192265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05192265, "Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05192265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*